<DOC>
	<DOCNO>NCT00004160</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness chemotherapy plus radiation therapy treat patient stage III non-small cell lung cancer surgically remove .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy Treating Patients With Stage III Non-small Cell Lung Cancer That Can Be Surgically Removed</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity gemcitabine paclitaxel combination radiotherapy patient locally advanced stage IIIA IIIB non-small cell lung cancer . II . Assess response rate , duration response , disease free survival failure patient population regimen . III . Determine pharmacokinetics gemcitabine paclitaxel chemoradiotherapy phase . OUTLINE : This dose escalation study gemcitabine . Induction phase : Patients receive gemcitabine IV 30 minute day 1 8 cisplatin IV 1 hour day 1 . Treatment repeat every 3 week 2 course . Chemoradiotherapy phase : Patients receive paclitaxel IV 1 hour gemcitabine IV 30 minute begin 2 hour paclitaxel infusion day 1 week 6 , 9 , 12 . Patients undergo conventional chest radiotherapy Monday though Friday week 6-11 . Cohorts 3-5 patient receive escalate dos gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 5 patient experience dose limit toxicity . PROJECTED ACCRUAL : A minimum 17 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advance , unresectable non small cell lung cancer Stage IIIA IIIB Local , unresectable recurrence primary surgery allow Measurable evaluable disease No contralateral pleural effusion ( ) noncontiguous pleural implant T4 tumor small ipsilateral pleural effusion allow PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No prior myocardial infarction within past 6 month No congestive heart failure No uncontrolled arrhythmias Pulmonary : FEV1 great 800 mL Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No history hypersensitivity drug formulate Cremophor EL No malignancy within past 5 year , except : Nonmelanomatous skin cancer Carcinoma situ cervix No overt psychosis major debilitate disorder would preclude compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>